Navigation Links
Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
Date:7/26/2010

or only six to 10 months.(i) The single-agent activity with durable disease control and favorable tolerability observed in this study indicate that carfilzomib has the potential to alter the natural course of this deadly disease."

"Carfilzomib has the potential to be an important therapy in multiple myeloma and exemplifies the Onyx vision to build a leading oncology company by developing innovative targeted therapies," said N. Anthony Coles, M.D., President and Chief Executive Officer of Onyx Pharmaceuticals. "We are committed to bringing this promising treatment to patients as quickly as possible by pursuing an accelerated approval pathway in the U.S., while simultaneously moving forward with two Phase 3 studies. The first study, ASPIRE, is designed to support full carfilzomib registration in the U.S. in earlier-stage patients who have relapsed following initial lines of therapy, and the second study is designed to support approval in relapsed and refractory patients in Europe."

Trial Design

The 003-A1 study was an open-label, single-arm Phase 2b trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma whose disease was refractory to their last treatment regimen and who had received at least two prior therapies, including bortezomib, either thalidomide or lenalidomide, an alkylating agent, glucocorticoids and an anthracycline. Refractory disease was defined as < 25% response or progression during therapy or within 60 days after completion of therapy.(ii) Patients enrolled in the 003-A1 trial had received a median of five prior therapeutic regimens, corresponding to a median of 13 anti-myeloma agents. Patients received carfilzomib at 20mg/m2 for the first cycle followed by 27mg/m2 thereafter for up to 12 cycles. Patients who completed the 12 cyc
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
2. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
5. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
6. Lotus Pharmaceuticals Terminates SEDA
7. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
8. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
9. Endo Pharmaceuticals to Announce Second Quarter 2010 Financial Results on July 30, 2010
10. Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector
11. Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or ... cloud-based platform, exchange, and big data solutions in ... launched its mobile app for Healthcare One Pass, ushering ... mobile devices. The Company jointly hosted the launch ceremony ... and Shenzhen News Net.   The mobile app ...
(Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
Breaking Medicine Technology:CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... EDISON, N.J., Dec. 7 Q-Med AB and Oceana Therapeutics, Inc. ... primary endpoints for the treatment of fecal incontinence. , Q-Med AB ... the FDA during the first quarter of 2010 based on the ... result of years of hard work as we developed a product ...
... , SAN DIEGO, Dec. 7 CareFusion (NYSE: ... six new Pyxis® medication management products at the 44th American ... Exhibition Dec. 6 -10 in Las Vegas. , CareFusion is ... Pyxis products rank number one in user satisfaction ratings by ...
Cached Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3
(Date:7/7/2015)... , ... July 07, 2015 , ... ... Health (NIWH) have jointly announced a partnership focused on providing knowledge organizing ... case studies. The study will be conducted with NIWH trained patient health educators, ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... has announced the release of Service Pack 5600 for its Call Accounting ... of enhancements to the already robust capabilities of the reporting platform, including ...
(Date:7/7/2015)... ... July 07, 2015 , ... Clarion ... labels, has been featured in the latest issue of In Compliance Magazine, a ... In Compliance delivers the latest news, standards updates, technical explanations and guidance, ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... they have been selected by the Department of Vermont Health Access to provide ... Management Information System (MMIS) and Integrated Contact Center System project. , Vermont is ...
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile testing is ... AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive drugs and ... technologies and genetic engineering also open lucrative opportunities for the market players. , ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 3Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3
... of Medicine have identified "secondary over-triage" as a potential area ... of over-triage occurs when patients are transferred twice, and discharged ... findings will be published in the September 10th issue of ... the number of times patients are transferred, we can evaluate ...
... the John Theurer Cancer Center at Hackensack University Medical Center ... the Food & Drug Administration,s (FDA) recent fast tracking of ... its decision largely on the results of a pivotal study ... on August 19, 2010 the same day the agency ...
... , THURSDAY, Sept. 9 (HealthDay News) -- A new study ... a child,s brain is maturing properly, potentially providing an early ... the strategy could turn an ordinary brain scan into a ... if kids are growing at an appropriate rate. "It,s ...
... 2010 News media and others interested in the ... a series of American Chemical Society (ACS) Webinars, focusing ... small business funding programs. Scheduled for Thursday, Sept. ... ACS Webinar will feature Josephine Yuen, Ph.D., NSF Program ...
... HealthDay Reporter , THURSDAY, Sept. 9 (HealthDay News) -- Two new ... smoking men who may become fathers, and in sons born to ... both men and women who hope to conceive should kick the ... biological effect of smoking on spermatozoa DNA integrity," said the lead ...
... , WEDNESDAY, Sept. 8 (HealthDay News) -- Statins, lauded ... attacks and strokes, may also reduce the risk of ... "We found that statin users who purchased their medication ... a long follow-up period," said lead researcher Gabriel Chodick, ...
Cached Medicine News:Health News:Promising treatment for metastatic melanoma 'fast tracked' by FDA 2Health News:Promising treatment for metastatic melanoma 'fast tracked' by FDA 3Health News:Brain Scans Could Spot Developmental Problems in Kids 2Health News:American Chemical Society Webinar focuses on NSF's small business funding programs 2Health News:Smoking Could Harm Sperm, Study Finds 2Health News:Smoking Could Harm Sperm, Study Finds 3Health News:Statins May Guard Against Rheumatoid Arthritis 2Health News:Statins May Guard Against Rheumatoid Arthritis 3
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Medicine Products: